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odck@tom.com (CAbstract In this paper controlled porosity osmotic pump tablets (CPOPT) for salvianolic acid
(SA) were prepared and optimized with experimental design methods including an artiﬁcial neutral
network (ANN) method. Three causal factors, i.e., drug, osmotic pressure promoting agent rate,
PEG400 content in coating solution and coating weight, were evaluated based on their effects on
drug release rate. The linear correlation coefﬁcient of the accumulative amount of drug release and
the time of 12 h, r(Y1), and the sum of the absolute value between measured and projected values,
Y2, were used as outputs to optimize the formulation. The weight expression Y¼(1Y1)2þY22 was
used in the calculation. Furthermore, the ANN and uniform design gave similar optimization
results, but ANN projected the outputs better than the uniform design. This paper showed that the
release rate of salvianolic acid B and that of the total salvianolic acid was consistent in the
optimized formulation.
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Preparation and optimization of osmotic tablets using the ANN method 651. Introduction
Salvianolic acid is a water-soluble active ingredient of the
traditional Chinese medicine Salvia miltiorrhiza Bge. It was
developed as powder for intravenous injection and is used for
the treatment of coronary heart disease and cerebral arterio-
sclerosis in clinics1. However, after injection, the drug is
distributed and eliminated rapidly and it is difﬁcult to
maintain effective plasma drug concentration for a prolonged
period of time. Only less than 1% of the initial drug plasma
concentration remains after 7 h by i.v. administration. Repe-
titive multiple daily intravenous administrations of small equal
doses are needed to achieve efﬁcacy, but it leads to poor
patient compliance2.
This paper aims to use the technology of controlled
porosity osmotic tablet to deliver salvianolic acid at a zero-
order rate for 12 h and to achieve prolonged plasma drug
concentration in vivo, to reduce dosing frequency, and to
improve compliance and therapeutic efﬁcacy.
Salvianolic acid is made up of salvianolic acid A, salvianolic
acid B, salvianolic acid C, rosmarinic acid, salianic acid,
protocatechuic aldehyde (acid), and other minor components.
These components have a similar structure formula (salvianic
acid A), but different half-life and absorption rate constant2.
Although salvianolic acid B is one of the most important
composition and is the content of the highest among salvianolic
acid, its content is only 60.5% of the total crude extract, it is not
adequate to use only salvianolic acid B as an indicator to
control the drug release in the osmotic pump tablets. In order
to determine the controlled release rate of salvianolic acid
from a dosage form, an HPLC–UV method was developed for
salvianolic acid B, and an UV method for the total salvianolic
acid. The structural formulas of salvianolic acid are shown in
Fig. 1.
A recently developed computer-based artiﬁcial neural net-
works (ANN) technology has shown to be very useful for
formulation screening and optimization, and its results are
compatible to traditional statistical approach3–6. The distinct
features of the ANN make the model itself very useful
in situations when a functional inter-dependence between the
inputs and outputs is not clear. In this paper, we pioneeredFigure 1 Structural formuapplication of ANN for the optimization of the formulation
composition of the controlled porosity osmotic pump tablet7,
a practice and learning that may potentially be of beneﬁt to
the industry.
2. Materials and methods
2.1. Material
The following listed drug, excipients, and chemicals were
purchased from commercial sources and used as received:
salvianolic acid (Shanghai Pharmavan Medicine Development
Co., Ltd., Shanghai, China), salvianolic acid B (National
Institute For the Control of Pharmaceutical and Biological
Product, Beijing, China), sucrose (Fuchen Chemical Reagent),
lactose (Fuchen Chemical Reagent), NaCl (Fuchen Chemical
Reagent), cellulose acetate (54.5–56.0 wt% acetyl content,
Sinopharm Chemical Reagent Co., Ltd., Shanghai, China),
diethylphthalate (Tianjin Damao Chemical reagent Factory,
Tianjin, China), polyethylene glycol (PEG) 400 (Guangzhou
Guanghua Chemical Factory Co., Ltd., Shantou, Guang-
dong), acetone (Tianjin Damao Chemical Reagent Factory,
Tianjin, China), isopropyl alcohol (Tianjin Damao Chemical
Reagent Factory, Tianjin, China), HPLC grade acetonitrile
(Dima Technology Inc., USA), HPLC grade methanol (Dima
Technology Inc., USA). Solvents of reagent grade and double
distilled deionized water were used in all the experiments.
2.2. Preparation of the CPOPT of salvianolic acid
The core tablets of salvianolic acid were prepared by wet
granulation and 200 tablets were made. Salvianolic acid was
mixed with all the excipients except for magnesium stearate
(Table 1) and was passed through 60-mesh sieve. The blend
was mixed for 10 min. The mixture was granulated with
dehydrated ethanol and the resulting wet mass was passed
through 20-mesh sieve. The granules were dried at 40 1C
(approximately for 10 min) to get a loss on drying (LOD)
value between 0.9% and 1.1%. They were then passed through
a 20-mesh sieve. These sized granules were then blended withlas of salvianolic acid.
Table 1 Core formulations of salvianolic acid.
Ingredient (mg/tablet) Core code
A1 A2 A3 A4 A5 A6
Salvianolic acid 100 100 100 100 100 100
Sucrose 300 – – 100 150 200
Lactose – 300 – 100 150 200
NaCl – – 300 – – –
Magnesium stearate 2.0 2.0 2.0 1.5 2.0 2.5
Table 2 Coating formulations for salvianolic acid core
formulations.
Ingredient Coating code
B1 B2 B3 B4 B5
Cellulose acetate (g) 30.0 30.0 30.0 30.0 30.0
Diethylphthalate (mL) 4.5 6.0 7.5 6.0 6.0
PEG400 (mL) 9.0 9.0 9.0 6.0 12.0
Acetone (mL) 800 800 800 800 800
Isopropyl alcohol (mL) 200 200 200 200 200
Table 3 Uniform design (U12). Osmogents is the mixture
of lactose and sucrose in the ratio of 1:1 (see Table 1).
Formulation Factor level
Coating
weight, X1
(%)
PEG400,
X2 (%)
Drug:osmogents,
X3
F1 2 40 1:2
F2 3 40 1:3
F3 4 40 1:4
F4 2 40 1:4
F5 3 30 1:2
F6 4 30 1:3
F7 2 30 1:3
F8 3 30 1:4
F9 4 20 1:2
F10 2 20 1:2
F11 3 20 1:3
F12 4 20 1:4
Wen-Jin Xu et al.66magnesium stearate and compressed into tables with an
average weight of 40075 mg (A1–A4), 30075 mg (A5),
and 50075 mg (A6), using a single-stroke tablet-punching
machine (Far East Pharmach., Shanghai, China) ﬁtted with
9.5, 9.0, and 10.0 mm round standard concave punches.
Formulas of different core formulations of salvianolic acid
are listed in Table 1.
The core tablets of salvianolic acid were coated in a stainless
steel pan (Taizhou Jintai Pharmaceutical Machinery Co., Ltd.,
Jiang Su, China) with a coating solution whose composition is
given in Table 2. The coating solution was prepared by adding
various components to the solvent mixture in a sequential manner.
The component added was allowed to dissolve before the next
component was added. The coating conditions were set as follows:
stainless steel pan, 300 mm diameter; 6 bafﬂes; rotation rate of the
pan, 35 rev./min; nozzle diameter of spray gun, 1 mm; spray rate,
8–10 mL/min; spray pressure, 2 bar; and drying temperature,
40 1C. Coating was continued until desired target weight gain
was obtained on the tablets. Thereafter, in all cases, active tablets
were dried at 40 1C for 12 h prior to evaluations.
2.3. In vitro dissolution and HPLC analysis
In vitro drug release of the formulations was carried out in a
dissolution apparatus with a basket setting (China Pharmaco-
poeia 2010). Operating conditions were 3770.5 1C, and a
basket speed of 100 rev./min with 900 mL of distilled water as
the medium. The samples were withdrawn (10 mL) at different
time intervals and replaced with an equivalent amount of fresh
medium. The dissolution samples, after ﬁltration through
0.45 mm nylon membrane ﬁlters, were analyzed using a
validated HPLC method at 286 nm8. The column used was a
Diamonsil 18C (250 mm 4.6 mm, 5 mm). The mobile phase
consisted of methanol:acetonitrile:water:methanoic acid
(30:10:59:1, v/v) at a ﬂow rate of 1.0 mL/min. The temperature
of the column oven was maintained at 35 1C. After analyzingthe drug content in the dissolution samples, corrections were
made for the volume replacement, and a graph of cumulative
percentage of drug release versus time was plotted.
2.4. Evaluation parameters
The weight expression, Y¼(1Y1)2þY22, consists of two
optimization parameters, which are the linear correlation
coefﬁcient of the accumulative amount of drug release and
the time of 12 h, Y1(r), and the sum of the absolute values
between measured and projected theoretical values, Y2
(Y2 ¼
Pn
i 9yiy0i9, i¼1, 2, 3, 4, 5, 6). When the value of Y
approximates to zero, the ideal drug release at a zero-order
rate for 12 h will be obtained.
2.5. Uniform design
In the above principles, the number of the levels of each factor
is assumed to be the same, but in fact, this assumption is not
always correct. When this situation is encountered, sample
choice can be carried out by repetitively arranging the levels of
the factor whose level number is less to ensure this assumption
(Table 3).
2.6. Artiﬁcial neural networks
ANN models can be classiﬁed into three categories based on
their functions9: associating networks, feature extracting net-
works, and non-adaptive networks. Among these three types
of ANN models, associating networks can be employed to
develop controlled release formulations, because the relation-
ship between the drug release proﬁles of the controlled release
drug delivery systems and formulation and process factors is
not linear, and is not well understood.
Hence, the focus of this review is on the usefulness of
associating network models to design and formulate the
controlled release drug delivery systems. Rumelhart et al.10
ﬁrst introduced the associating ANN based on the delta rule
back-propagation of errors. Since then, many learning algo-
rithms based on the back-propagation have been developed.
Figure 3 Graph presentation of experimental points (face- cen-
tered central composite design); X1—coating weight; X2—amounts
of PEG400; X3—drug:osmogents ratio; () low level of factor and
(þ) high level of factor.
Table 5 Summary computation result and the best value
result of uniform design.
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composition and process optimization. The back-propagation
ANN models have multi-layered architecture, as shown in
Fig. 2.
A full 23 factorial design was used in this investigation3.
Three factors of the formulation were chosen for studying
their effect on drug release, and each on three levels. The three
factors are factor X1—coating weight; factor X2—the amounts
of PEG400; and factor X3—drug:osmogents ratio. Seven
additional experimental points with middle levels of factors
in the formulations are listed in Table 4. Together they
constituted a face-centered central composite design.
The experimental points of 23 factorial design can be
presented on the eight corners of a cube and additional
experimental points on the six sides of the cube and one in
the center of the cube (Fig. 3).
3. Results
3.1. Uniform design
The summary computation result and the best value result of
uniform design are shown in Table 5 and in Figs. 4 and 5.Figure 2 Back-propagation ANN models.
Table 4 Experimental design for full 23 factorial design
and additional experimental points for artiﬁcial neural
networks. Osmogents is the mixture of lactose and sucrose
in the ratio of 1:1 (see Table 1).
Formulation Factor level
Coating
weight,
X1 (%)
PEG400,
X2 (%)
Drug:osmogents,
X3
F1 2 20 1:2
F2 4 20 1:2
F3 2 40 1:2
F4 4 40 1:2
F5 2 20 1:4
F6 4 20 1:4
F7 2 40 1:4
F8 4 40 1:4
F9 2 30 1:3
F10 4 30 1:3
F11 3 40 1:3
F12 3 20 1:3
F13 3 30 1:4
F14 3 30 1:2
F15 3 30 1:3
Parameter Result
Regression equation Y¼0.845 8þ100.313
3X12.268 5X3þ3 728.888
9X1
2þ0.989 9X3293.694
4X1X3
Sum of squares of
residual error, Q
2.152 8
Standard deviation, S 0.599 0
Multiple correlation
coefﬁcient, R2
0.937 5
F value used for the
signiﬁcance test of
regression, F
8.706 1
Ymin 0.015 3
X1–X3 0.020 0; 0.200 0; 2.166 7
Figure 4 Three-dimensional presentation of the effect of coating
weight (X1) and drug:osmogents ratio (X3) on the weight expres-
sion, Y¼ (1Y1)2þY22.
Figure 5 Two-dimensional presentation of the effect of coating
weight (X1) and drug:osmogents ratio (X3) on the weight expres-
sion, Y¼(1Y1)2þY22.
Figure 6 Three-dimensional presentation of the effect of coating
weight (X1), the amounts of PEG400 (X2), and the drug:osmogents
ratio (X3) on the expression y¼ log((1Y1)2þY22).
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Because it is difﬁcult to observe stereographs, the optimized
results were shown as three-dimensional presentation (Fig. 6).
The rational result proved that when the value Y1 approx-
imates to 1, the value Y2 approximates to 0 (the value Y2 is
inversely proportional to the value Y1, Fig. 7).
3.3. Formulation optimization
The predicted result of optimized formulation in the uniform
design and artiﬁcial neural networks were shown in Table 6.
Fig. 8 showed that the actual in vitro dissolution proﬁles were
experimentally determined for these two formulations. Com-
paring the difference between the determined and predicted
values in two optimization techniques, we found that the
predicted result of the most appropriate formulation in
artiﬁcial neural networks was better than in uniform design
(Table 7). In vitro dissolution proﬁles showed that the release
rate of salvianolic acid B matches with that of the total
salvianolic acid in the optimized formulation of artiﬁcial
neural networks (Fig. 9).
3.4. Release models and kinetics
In order to describe the kinetics of drug release from the
preparations, various mathematical equations have been
proposed. The zero-order equation (Eq. (1)), the ﬁrst-order
equation (Eq. (2)), and the Higuchi model (Eq. (3)) were used
in the present study:
Qt ¼ k0T ð1Þ
lnQt ¼ lnQ0k1T ð2Þ
Qt ¼ kST1=2 ¼ kHT1=2 ð3Þ
where Qt is the amount of drug released in time T, Q0 is the
initial amount of drug in the tablet, S is the surface area of the
Figure 7 Correlation between linear correlation coefﬁcient of the
accumulative amount of drug release and the time of 12 h, Y1 (r),
and the sum of the absolute values between the determination and
ideal values, Y2.
Table 6 Synopsis of the predicted result in the uniform
design and artiﬁcial neural networks.
Formulations Ingredient Uniform
design
Artiﬁcial
neural
network
Core Salvianolic acid
(mg)
100 100
Sucrose (mg) 110 100
Lactose (mg) 110 100
Magnesium
stearate (mg)
1.6 1.5
Coating Cellulose acetate
(g)
30.0 30.0
Diethylphthalate
(mL)
6.0 6.0
PEG400 (mL) 6.0 12.0
Acetone (mL) 800 800
Isopropyl alcohol
(mL)
200 200
Figure 8 In vitro dissolution proﬁles for formulations optimized
by different methods.
Figure 9 In vitro dissolution proﬁles of the total salvianolic acid
and salvianolic acid B.
Table 7 Comparison of the difference between the mea-
sured and predicted values in two optimization techniques.
Weight expression
(Y¼(1Y1)2þY22)
Uniform
design
Artiﬁcial neural
network
Predicted value 0.015 0.093
Determination value 1.114 1.102
Difference 1.099 1.009
Table 8 Fitting of drug release data from optimized
formulation with various mathematical models.
Model Parameters used to assess the ﬁt of model
R2 r Intercept Slope
Zero order 0.996 1 0.998 0 0.121 5 0.066 0
First order 0.934 5 0.966 7 0.125 3 0.084 4
Higuchi 0.995 2 0.997 6 0.245 3 0.324 5
Preparation and optimization of osmotic tablets using the ANN method 69tablet, and k0, k1, and kH are the release rate constants for the
zero-order, the ﬁrst-order, and the Higuchi model rate
equations, respectively.
Dissolution data of the optimized formulation was ﬁtted
with various mathematical models (zero-order, ﬁrst-order, and
Higuchi) in order to describe the kinetics of drug release after
in situ formation of delivery pores. The coefﬁcient of determi-
nation (R2) and the correlation coefﬁcient (r) were used as
criteria for choosing the most appropriate model11. Drug
release from optimal formulations ﬁtted well into the zero-
order model (Table 8).
4. Discussion
Controlled release formulations of salvianolic acid were
developed based on osmotic technology. The effect of three
different formulation variables was evaluated for the optimi-
zation of drug release proﬁle. The mixture of lactose:sucrose
ratio 1:1 was chosen as osmogents, and the amounts of
osmogents tablet core were shown to have an impact on
Wen-Jin Xu et al.70the release of salvianolic acid. When the osmogents were
excessive, the saturated osmotic pressure was too high to
control the drug release. Although no signiﬁcant difference
was observed in drug release rate with the hardness of
core tablets as a variable, the tablets with low hardness
can cause abrasion of tablet core and crush during the coating
process. The release rate of salvianolic acid was found to
be inversely proportional to the concentration of the plastici-
zer. The salvianolic acid release rate increased as the pore-
forming substance in the coated membrane increased. The
salvianolic acid release rate from a microporous membrane
was affected by and is inversely proportional to overall
coating weight.
The optimization of formulation screening is a profound
process. First, the selection and conﬁrmation of the type and
range of factors and optimization parameters to be evaluated
for the target release proﬁle are critical. Second, the use of the
most appropriate experiment design method is very important.
If optimization parameters are more than one and their
dimension varies, it is very difﬁcult to judge which weight
expression to choose as the evaluation criterion. In this paper,
the weight expression, Y¼(1Y1)2þY22, consisted of two
optimization parameters, which are the linear correlation
coefﬁcient of the accumulative amount of drug release and
the time of 12 h, Y1(r), and the sum of the absolute values
between the measured and predicted values, Y2. When the
value Y approximates to zero, the target drug release at a zero-
order rate for 12 h will be obtained. It proved the weight
expression rational that Y1(r) is inversely proportional to Y2 in
artiﬁcial neural networks. At the same time, the predicted
result of the most appropriate formulation in artiﬁcial neural
networks is more relevant than that in the uniform design. In
the actual in vitro dissolution proﬁles, we found that the
release rate of salvianolic acid B matched with that of the total
salvianolic acid in the optimized formulation of artiﬁcial
neural networks.References
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